CCND2 and Familial prostate cancer: Independent clinical data analysis (18 available clinical data sets, 1095 prostate samples), performed by Chen et al. (2017), highlighted the potential role of CCND2 in risk stratification and targeted therapy in men with advanced prostate cancer.